Physician profile
Laura Droege
NPI 1174174635
$3,202.69
in general payments reported to CMS, 2019-2025
19 companies · $644 in 2025
The $644 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $334 · 2023: $1,505 · 2024: $719 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386 · Travel and Lodging: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.98 |
| Travel and Lodging | $482.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,112.00 | 2023-2025 | Linq II |
| Boston Scientific Corporation | $383.46 | 2022-2025 | Watchman Flx |
| Recor Medical INC | $261.34 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.13 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $200.93 | 2023-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $133.68 | 2024 | Amvuttra |
| Edwards Lifesciences Corporation | $129.14 | 2022 | |
| Merck Sharp & Dohme LLC | $108.87 | 2022-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $108.46 | 2025 | |
| Pfizer INC. | $99.02 | 2023-2025 | |
| Amgen INC. | $92.38 | 2022-2023 | Repatha |
| Cvrx, INC. | $78.60 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $71.83 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $55.11 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $48.71 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $35.25 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $17.04 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $15.40 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $14.34 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Droege listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.